Many studies have shown that TP53 mutations play a negative role in antitumor immunity.
Introduction
p53 is one of the most important tumor suppressor which is involved in regulation of a wide range of cancer-associated pathways, such as cell cycle, apoptosis, DNA damage repair, metabolism, immune and inflammation, angiogenesis, and metastasis (1) . Its encoding gene TP53 is the most frequently-mutated gene in human cancers and the TP53 mutation is often associated with a worse prognosis in cancer (2). A number of studies have suggested that p53 plays an important role in tumor immune regulation (3) (4) (5) (6) (7) (8) (9) (10) (11) . Notably, most of these prior studies consistently showed that p53 played a positive role in antitumor immunosurveillance (3-8, 10, 11). As a result, TP53 mutations often inhibited antitumor immunity and cancer immunotherapy response (7, 10). However, a few studies have reported that TP53 mutations could promote antitumor immune activity and immunotherapy response (9, 11, 12). These contradictory findings suggest that the correlation between TP53 mutations and tumor immunity could be cancer type dependent.
p53 plays a key role in maintaining chromosomal/genomic stability (1) . Accordingly, TP53 COAD and GI cancers in the immunotherapy setting rather than in the non-immunotherapy setting ( Figure 4A ) could be attributed to the better immunotherapy response in the TP53wildtype subtype than in the TP53-mutated subtype of COAD and GI cancers. On the other hand, the negative correlation between TP53 mutations and OS in LUAD in the non-immunotherapy setting rather than in the immunotherapy setting ( Figure 4A ) could be a consequence of the better immunotherapy response in TP53-mutated LUAD than in TP53-wildtype LUAD. This speculation was confirmed in a LUAD cohort (Dong cohort (9)) receiving anti-PD-1/PD-L1 immunotherapy where TP53-mutated LUAD had a 1.5 times higher immunotherapy response rate (57.1%) than TP53-wildtype LUAD (37.5%) and TP53-mutated LUAD showed a better OS than TP53-widtype LUAD (9). These results suggest that the association between TP53 mutations and immunotherapy response is cancer type dependent. This conclusion can be evidenced by two recent studies showing that TP53 mutations could promote immunotherapy response in LUAD (9) and inhibit immunotherapy response in melanoma (10). Furthermore, we found that PD-L1 expression levels exhibited a significant positive correlation with TP53 mutations in BRCA and LUAD while a significant inverse correlation with TP53 mutations in STAD, COAD, and HNSC (Student's t test, P<0.05) ( Figure 4B ). This could explain why TP53mutated LUAD had a better immunotherapy response than TP53-wildtype LUAD and TP53mutated COAD had a worse immunotherapy response than TP53-wildtype COAD since PD-L1 expression is a biomarker for anti-PD-1/PD-L1 immunotherapy response in cancer (18) .
Discussion
A number of studies have revealed that cellular context is essential to p53 function and activity (1, 19) . In this study, we demonstrated that regulation of tumor immunity by p53 was cancer type dependent. We found that the correlation between TP53 mutations and tumor immunity was positive in BRCA and LUAD while was negative in STAD, COAD, and HNSC. To our knowledge, this is the first study showing distinct correlations of TP53 mutations with tumor immunity in different cancer types. Interestingly, we found that even in the cancers originating from the same organ, the correlations of TP53 mutations with tumor immunity could be distinct.
For example, the correlation between TP53 mutations and tumor immunity tended to be negative in LUSC (Supplementary Figure S2A ) versus the positive correlation between TP53 mutations and tumor immunity in LUAD ( Figure 1A) . Moreover, TP53 mutations were associated with a worse OS in LUSC in the immunotherapy setting (Samstein cohort) (log-rank test, P=0.046) (Supplementary Figure S2B ) while showed no a significant association with OS in LUAD in this cohort (log-rank test, P=0.335) ( Figure 4A ). p53 is a significant protector of genome stability and TP53 mutations often comprise the p53 function in maintaining genome stability (20) . As a result, TP53-mutated cancers tend to exhibit higher TMB and TAL than TP53-wildtype cancers ( Supplementary Table S1 . The gene sets that represent different immune signatures.
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Supplementary Figure S1 . A number of HLA genes show significantly higher expression levels in high-TMB cancers than in low-TMB cancers and significantly lower expression levels in high-TAL cancers than in low-TAL cancers (Student's t test, P<0.05).
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